Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 305

1.

Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.

Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, Wang H, Wang Z.

Sci Rep. 2017 Jul 13;7(1):5319. doi: 10.1038/s41598-017-05464-0.

2.

Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.

Cinar P, Ko AH.

Chin Clin Oncol. 2017 Jun;6(3):29. doi: 10.21037/cco.2017.06.13.

3.

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.

van Helden EJ, Menke-van der Houven van Oordt CW, Heymans MW, Ket JCF, van den Oord R, Verheul HMW.

Cancer Metastasis Rev. 2017 Jul 10. doi: 10.1007/s10555-017-9668-y. [Epub ahead of print] Review.

PMID:
28695301
4.

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M.

Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.

5.

Toxicity of Chemotherapy Regimens in Advanced and Metastatic Pancreatic Cancer Therapy: A Network Meta-Analysis.

Wang XF, Huang WF, Nie J, Zhou Y, Tan DW, Jiang JH.

J Cell Biochem. 2017 Jul 6. doi: 10.1002/jcb.26266. [Epub ahead of print]

PMID:
28681936
6.

Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.

Pulvers JN, Marx G.

Asia Pac J Clin Oncol. 2017 Jun 27. doi: 10.1111/ajco.12694. [Epub ahead of print] Review.

PMID:
28653815
7.

The use of antioxidant agents for chemotherapy-induced peripheral neuropathy treatment in animal models.

Carvalho LF, Silva AMF, Carvalho AA.

Clin Exp Pharmacol Physiol. 2017 Jun 26. doi: 10.1111/1440-1681.12803. [Epub ahead of print] Review.

PMID:
28649767
8.

Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.

Petrelli F, Inno A, Ghidini A, Rimassa L, Tomasello G, Labianca R, Barni S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and Cremona Hospital.

Eur J Cancer. 2017 Aug;81:174-182. doi: 10.1016/j.ejca.2017.05.025. Review.

PMID:
28633088
9.

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.

Liu GF, Li GJ, Zhao H.

J Cell Biochem. 2017 Jun 13. doi: 10.1002/jcb.26210. [Epub ahead of print]

PMID:
28608558
10.

Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy.

Faugeras L, Dili A, Druez A, Krug B, Decoster C, D'Hondt L.

Crit Rev Oncol Hematol. 2017 Jul;115:59-66. doi: 10.1016/j.critrevonc.2017.03.029. Epub 2017 Mar 29. Review.

11.

FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.

Liu Y, Zheng Z, Zhang Q, Zhou X, Feng Y, Yan A.

Onco Targets Ther. 2017 May 18;10:2621-2633. doi: 10.2147/OTT.S138011. eCollection 2017.

12.

Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.

Zhao J, van Mierlo KMC, Gómez-Ramírez J, Kim H, Pilgrim CHC, Pessaux P, Rensen SS, van der Stok EP, Schaap FG, Soubrane O, Takamoto T, Viganò L, Winkens B, Dejong CHC, Olde Damink SWM; Chemotherapy-Associated Liver Injury (CALI) consortium.

Br J Surg. 2017 Jul;104(8):990-1002. doi: 10.1002/bjs.10572. Epub 2017 May 25. Review.

PMID:
28542731
13.

FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S.

JAMA Oncol. 2017 Jul 13;3(7):e170278. doi: 10.1001/jamaoncol.2017.0278. Epub 2017 Jul 13.

PMID:
28542671
14.

Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis.

Zhou M, Yu P, Hernick Davin DB, Li Y, Wang Y, Fu L, Zhang J.

Oncotarget. 2017 May 9. doi: 10.18632/oncotarget.17725. [Epub ahead of print]

15.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.

Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, Yonemura Y, Li Y.

Oncotarget. 2017 Apr 27. doi: 10.18632/oncotarget.17497. [Epub ahead of print] Review.

16.

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.

De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, Tombolini V.

BMC Cancer. 2017 May 12;17(1):325. doi: 10.1186/s12885-017-3323-4.

17.

FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Leal F, Ferreira FP, Sasse AD.

Clin Colorectal Cancer. 2017 Mar 24. pii: S1533-0028(16)30244-4. doi: 10.1016/j.clcc.2017.03.012. [Epub ahead of print]

PMID:
28433602
18.

Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.

Fu XL, Fang Z, Shu LH, Tao GQ, Wang JQ, Rui ZL, Zhang YJ, Tian ZQ.

Oncotarget. 2017 May 23;8(21):34340-34351. doi: 10.18632/oncotarget.16127.

19.

Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.

Derksen TM, Bours MJ, Mols F, Weijenberg MP.

Evid Based Complement Alternat Med. 2017;2017:7916031. doi: 10.1155/2017/7916031. Epub 2017 Mar 16. Review.

20.

Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.

Zheng J, Feng X, Hu W, Wang J, Li Y.

Medicine (Baltimore). 2017 Mar;96(13):e6487. doi: 10.1097/MD.0000000000006487. Review.

Supplemental Content

Loading ...
Support Center